Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IVACC.STthis companyIntervacc AB (publ)	SEK 0.79	-3.42×	1×	13.68×	-1.72×	-653.1%	-335.6%	-422.5%	-402.3%	-29.4%	-30.9%	-24.4%	0×	2.43×	-6,527.54×	8.99×	0.0%	1	4.07	2	C
ACARIX.STAcarix AB (publ)	SEK 0.16	-6.28×	7.91×	41.02×	-6.37×	-225.0%	37.5%	-652.2%	-653.3%	-126.0%	-125.8%	-16.3%	0×	0.41×	0×	4.08×	0.0%	3	12.43	1	D+
ACE.STAscelia Pharma AB (publ)	SEK 0.53	-4.81×	3.67×	0×	-4.32×	-17.7%	0.0%	0.0%	0.0%	-76.7%	-73.4%	-19.8%	0.01×	0.67×	-13.46×	4.35×	0.0%	1	-8.91	2	C+
ELIC.STElicera Therapeutics AB (publ)	SEK 2.58	-13.74×	10.19×	0×	-12.25×	-80.7%	0.0%	0.0%	0.0%	-74.5%	-76.8%	-9.1%	0×	1.43×	-2,278.11×	6.75×	0.0%	1	32.08	1	C-
IMMU.STMendus AB (publ)	SEK 5.88	-2.58×	0.5×	0×	-2.16×	-84.5%	0.0%	0.0%	0.0%	-19.4%	-19.9%	-28.0%	0.03×	0.4×	-36.63×	2.7×	0.0%	1	-0.16	2	B-
IRLAB-A.STIRLAB Therapeutics AB (publ)	SEK 2.10	-1.2×	4.3×	2.3×	-0.91×	-160.0%	-160.7%	-160.7%	-191.4%	-358.1%	-152.2%	-41.8%	0.98×	0.59×	-5.13×	0.8×	0.0%	1	-3.89	2	C
Peer median	—	-4.81×	4.3×	0×	-4.32×	-84.5%	0.0%	0.0%	0.0%	-76.7%	-76.8%	-19.8%	0.01×	0.59×	-13.46×	4.08×	0.0%	1	-0.16	2	—